EASE SBS 2 Extension Trial of Glepaglutide in Short Bowel Syndrome

Phase 3, randomised, double-blind trial in short bowel syndrome (SBS) comparing Glepaglutide with Placebo (2 arms). Primary endpoints: Incidence and type of adverse events (AEs), Incidence and type of serious adverse events (SAEs) and adverse events of special interest (AESIs) and 8 more. Started Nov 2024; status: completed.